ArticleScientific reports2025
The combined effect of CRP and blood pressure on the risk of mortality in patients with type 2 diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To examine the effects of C-reactive protein (CRP) and blood pressure (BP) on the risk of all-cause mortality in diabetic patients. Data were obtained from the China Health and Retirement Longitudinal Study. Participants with type 2 diabetes in 2011 (baseline) and participated at least one subsequent survey (2013, 2015, and 2018) were included in this study. Participants were divided into 6 groups according to their CRP and BP status. Cox proportional hazard regression model was used to analyze the risk of all-cause mortality among different groups. This study included 1631 diabetic patients aged 60.7 ± 9.2 years old. During the 7-year follow-up period, 212 (13.0%) death occurred. High CRP (HR 1.94, 95% CI 1.45-2.61) and hypertension (HR 2.01, 95% CI 1.31-3.08) were independently associated with increased risks for all-cause mortality among participants. The respective HRs (95% CI) of mortality for participants in low CRP/prehypertension, low CRP/ hypertension, high CRP/normotension, high CRP/prehypertension, high CRP/hypertension group were 1.97 (1.12-3.48), 2.19 (1.24-3.88), 3.50 (1.67-7.33), 2.03 (1.00-4.09), and 4.79 (2.68-8.57), in comparison with the low CRP/normotension group. The combination of high CRP and high BP significantly increased the risk of all-cause mortality in Chinese diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.